Denali Therapeutics price target lowered to $35 from $40 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Denali Therapeutics (DNLI) to $35 from $40 and keeps an Overweight rating on the shares. The P...

Raccontata damarkets.businessinsider.com